Guidelines Issued to Improve NGS Workflow in Oncology
News Mar 24, 2017 | Original story from The Association for Molecular Pathology
The Association for Molecular Pathology (AMP), the premier global, non-profit molecular diagnostics professional society, has published consensus recommendations to help clinical laboratory professionals achieve high-quality sequencing results and deliver better care for cancer patients. The report, “Guidelines for Validation of Next Generation Sequencing (NGS)-based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists,” was released online ahead of publication in The Journal of Molecular Diagnostics.
“In this era of precision medicine, NGS has quickly become the method of choice for detecting multiple somatic variants, diagnosing disease, and predicting response to targeted therapies. However, the required analytical validation process remains challenging,” said Lawrence Jennings, MD, PhD, Attending Pathologist, Ann and Robert H. Lurie Children’s Hospital of Chicago, Working Group Chair, and AMP Member. “AMP convened and led a multidisciplinary subject matter expert working group with liaison representation from CAP to summarize current knowledge, expose challenges, and provide guidance on how to best validate these tests to ultimately improve patient care.”
AMP is in the process of providing a series of guidelines designed to improve the entire NGS workflow. The joint consensus recommendations are based on evidence from a review of published literature, empirical data, current laboratory practice surveys, feedback from multiple public meetings, and expert professional experiences. The latest report addresses NGS test development, optimization and familiarization, and best practices for establishing test performance characteristics. The recommendations emphasize the critical role of the molecular laboratory director in establishing and utilizing an error-based approach for patient risk management. Since these recommendations represent current best practice in a rapidly developing field, AMP anticipates a need for ongoing updates. The new report follows the previously published guidelines on interpreting oncology sequence variants. AMP plans on publishing the next companion paper in this series focusing on downstream NGS bioinformatics analysis later this year.
“With this series of guidelines, AMP continues to provide the cancer genomics community with the appropriate tools and guidance to better incorporate the latest scientific breakthroughs and technological innovations in molecular pathology,” said Marina N. Nikiforova, MD, Professor of Pathology at University of Pittsburgh Medical Center, Working Group Member, and 2016 AMP Clinical Practice Committee Chair. “Our hope is that we will soon see the widespread adoption of these guidelines leading to improvements in how molecular pathologists validate and provide high-quality NGS results to support our oncologists, pathologists, and most importantly, patients.”
Jennings, L. J., Arcila, M. E., Corless, C., Kamel-Reid, S., Lubin, I. M., Pfeifer, J., . . . Nikiforova, M. N. (2017). Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels. The Journal of Molecular Diagnostics. doi:10.1016/j.jmoldx.2017.01.011
This article has been republished from materials provided by The Association for Molecular Pathology. Note: material may have been edited for length and content. For further information, please contact the cited source.
Biological Fingerprint of Tuberculosis Meningitis Discovered in ChildrenNews
Children with tuberculosis meningitis have a biological fingerprint that can be used to assess the severity of the condition, help decide the best course of treatment, and provide clues for novel treatments.READ MORE
Exosomes Offer Significant Potential in Detecting and Treating DiseaseNews
Exosomes - tiny biological nanoparticles which transfer information between cells - offer significant potential in detecting and treating disease, the most comprehensive overview so far of research in the field has concluded.READ MORE
FDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer TherapiesNews
Oncomine Dx Target Test returns results in days, helping physicians rapidly develop treatment plans for the most common form of lung cancer.